215 related articles for article (PubMed ID: 22990650)
1. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.
Smith G; Ng MT; Shepherd L; Herrington CS; Gourley C; Ferguson MJ; Wolf CR
Br J Cancer; 2012 Oct; 107(8):1327-36. PubMed ID: 22990650
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
Nicholson HA; Sawers L; Clarke RG; Hiom KJ; Ferguson MJ; Smith G
Br J Cancer; 2022 Oct; 127(7):1340-1351. PubMed ID: 35778553
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
[TBL] [Abstract][Full Text] [Related]
4. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
Sawers L; Ferguson MJ; Ihrig BR; Young HC; Chakravarty P; Wolf CR; Smith G
Br J Cancer; 2014 Sep; 111(6):1150-8. PubMed ID: 25010864
[TBL] [Abstract][Full Text] [Related]
5. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
6. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
7. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
10. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
11. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
Li L; Wu M; Yang JX; Wan XR; Huang HF; Pan LY; Shen K; Lang JH; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):825-831. PubMed ID: 27916065
[No Abstract] [Full Text] [Related]
13. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
[TBL] [Abstract][Full Text] [Related]
14. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
15. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
[TBL] [Abstract][Full Text] [Related]
16. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
17. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study.
Kim HS; Kim TJ; Chung HH; Kim JW; Kim BG; Park NH; Song YS; Bae DS; Kang SB
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1513-20. PubMed ID: 19449027
[TBL] [Abstract][Full Text] [Related]
18. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
[TBL] [Abstract][Full Text] [Related]
20. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
